Efficacy and tolerability of a lotion containing triethyl citrate, ethyl linoleate, and GT peptide‐10 in the adjuvant treatment of hidradenitis suppurativa: Real‐life data. Issue 4 (11th April 2018)

• Record Type: Journal Article
• Authors: Skroza, N.; Mambrin, A.; Tolino, E.; Marchesiello, A.; Proietti, I.; Bernardini, N.; Potenza, C.
• Is Part Of: Dermatologic therapy. Volume 31:Issue 4(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-04-11
• Subjects: hidradenitis suppurativa -- topical therapy -- triethyl citrate ethyl linoleate G –peptide 10; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.12599
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Hidradenitis suppurativa (HS) is a chronic disorder of terminal follicular epithelium in the apocrine gland‐bearing areas. The long term therapy is based mainly on topical and/or systemic antibiotic use that could result in antibiotic resistance. The aim of our study was to present the real‐life experience based on the efficacy and tolerability of a novel lotion containing triethyl‐citrate, ethyl‐linoleate, and g‐peptide‐10 in the treatment of mild to moderate HS that has already shown effectiveness in acne treatment. This was an open‐label study on 30 patients of both sexes affected by HS. Patients were divided into two groups: 15 with Hurley I and 15 with Hurley II–III. The subjects were treated with the topical lotion, three‐times‐daily for eight weeks, with control at 4 ( T 1 ) and eight weeks ( T 2 ). Any other concomitant treatment (both topical and/or systemic) was avoided during study period. Improvement was observed in both Sartorius score grading system and inflammatory and noninflammatory lesion counts. The novel lotion has proved to be effective and well‐tolerated topical agent alone or in association with other topical and/or systemic tratments in HS, without side effects